Tests magnesium to prevent new irregular heartbeat in critically ill patients
Tests magnesium sulfate or placebo in adults in intensive care to prevent atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients
Key facts
- Where
- Hamilton, Kingston, and Ottawa, CanadaSee the 4 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in intensive care who need breathing support, medicines to support blood pressure or the heart, or who had a cardiac arrest. It tests whether magnesium can prevent new atrial fibrillation.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Adults admitted to intensive care (ICU) who have one or more of these: breathing support (non-invasive ventilation, high flow oxygen above 10L/min, or a ventilator for breathing failure) expected to last more than 24 hours; vasopressor or inotropic support expected to last more than 24 hours; or a cardiac arrest. They must have continuous heart monitoring.
- Earlier treatment
- People who have already had breathing or inotropic support in intensive care for more than 18 hours cannot join. People taking amiodarone by mouth or by continuous infusion cannot join.
Main reasons for not taking part
- Atrial fibrillation at the time of enrolment
- Cardiac surgery patients
- Patients on dialysis
- Needing magnesium treatment by injection or infusion (for example pre-eclampsia, asthma)
- Unlikely to survive more than 24 hours, or receiving palliative care
Read by machine on 9 November 2026.
Where in Canada
- St. Joseph's Healthcare HamiltonHamilton, CanadaNot yet recruiting
- Kingston Health Sciences CentreKingston, CanadaTaking people
- The Ottawa Hospital - Civic CampusOttawa, CanadaNot yet recruiting
- The Ottawa Hospital - General CampusOttawa, CanadaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dr. Stephanie Sibley
- Trial code
- NCT05829317
- Record updated
- 22 September 2025
- Original description
A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.Read full original descriptionShow less
Parenteral Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients - a Pilot Feasibility Study
A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.
Inclusion: Age ≥18 years; Admitted to an ICU with one or more of the following:; Non-invasive ventilation (including CPAP, Bipap and high flow oxygen (>10L/min) or invasive mechanical ventilation with an expected duration >24 hours for respiratory failure (hypercarbic or hypoxic); Vasopressor or inotropic support with an expected duration of >24 hours; Cardiac arrest; Continuous cardiac monitoring.
Exclusion: Receiving ICU intervention (Non-invasive ventilation (including high flow nasal canula), invasive mechanical ventilation or inotropic support) for >18 hours; Receiving IMV for airway protection only (for example, isolated head trauma); Patients receiving dialysis; Previously enrolled in this trial; Cardiac surgery patients; Patients requiring parenteral magnesium therapy (e.g. pre-eclampsia, asthma); Positive pregnancy test (females <50 years old); Active atrial fibrillation at the time of enrolment; On oral or continuous infusion of Amiodarone; Unlikely to survive >24 hours or palliative patients; Treating physician refuses enrollment.